MedTrace Logo

PPARgamma Activation by Losartan in Hypertensive Patients: The Importance of Losartan-Metabolites

NCT00561327 · Status: UNKNOWN · Type: OBSERVATIONAL

Last updated 2007-11-20

No results posted yet for this study

Summary

The purpose of this study is to determine whether losartan metabolites are effective in inducing PPARγ target genes in monocytes in losartan-treated patients.

Conditions

Interventions

DRUG

losartan

Daily treated with losartan 100mg for at least the past 2 months (retrospective, no new drug treatment/ intervention)

Sponsors & Collaborators

  • Charite University, Berlin, Germany

    collaborator OTHER

  • Merck Sharp & Dohme LLC

    collaborator INDUSTRY

  • German Heart Institute

    lead OTHER

Principal Investigators

  • Eckart Fleck, Prof · German Heart Institute

  • Ulrich Kintscher, Prof · Institute of Pharmacology Charite University Medicine Berlin Germany

Eligibility

Min Age
19 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-09-30

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00561327 on ClinicalTrials.gov